{
  "docId": "019de516-de84-709f-9864-0c2e708269aa",
  "docSlug": "d2a0e3b4a50bc196c7afb3f2c93e5906",
  "documentTitle": "Bausch+Lomb | Results Presentation Deck | 38 slides",
  "authorId": "bausch-lomb",
  "authorName": "Bausch + Lomb",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 34,
  "pageCount": 38,
  "prevPage": 33,
  "nextPage": 35,
  "slideType": "revenue_buildup",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 108,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 0.9,
  "imagePath": null,
  "slideHref": "/slides/019de516-de84-709f-9864-0c2e708269aa/34",
  "deckHref": "/decks/019de516-de84-709f-9864-0c2e708269aa",
  "deckJsonHref": "/decks/019de516-de84-709f-9864-0c2e708269aa.json",
  "deckAnchorHref": "/decks/019de516-de84-709f-9864-0c2e708269aa#slide-34",
  "components": [
    {
      "bbox": {
        "h": 0.02,
        "w": 0.109,
        "x": 0.04,
        "y": 0.945
      },
      "kind": "image",
      "text": "BAUSCH+LOMB",
      "attrs": {},
      "subkind": "logo",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76979448-97d4-4d8f-b19b-9c522fcf6bb8",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.106,
        "w": 0.744,
        "x": 0.16,
        "y": 0.873
      },
      "kind": "source-note",
      "text": "1. This is a non-GAAP measure or non-GAAP ratio. See Slide 1 and this Appendix for further information on non-GAAP measures and ratios.\n2. Effective in the first quarter of 2023, certain products historically included in the reported results of the Pharmaceuticals segment are now included in the reported results of the Vision Care segment and certain products included in the reported results of the Vision Care segment are now included in the reported results of the Pharmaceuticals segment. Management believes these movements are necessary in order to better align these products with the groupings of similar products. The net impact of these product movements was not material to the periods presented. Prior period presentations of segment revenues have been conformed to the current segment reporting structure.\n3. The impact for changes in foreign currency exchange rates is determined as the difference in the current period reported revenues at their current period currency exchange rates and the current period reported revenues revalued using the monthly average currency exchange rates during the comparable prior period.\n4. As of the first quarter of 2023, certain products were recategorized across the consumables, implantables and equipment product categories. This change was made as management believes this better aligns these products in their respective categories. Prior period presentations of product categories have been conformed to current product category structure to allow investors to evaluate results between periods on a consistent basis.\n5. Contact Lens Revenue Impact of distribution facility disruptions is approximately $5M.",
      "attrs": {},
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2d863886-6077-41c8-b1b9-0ba8e03060ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.702,
        "w": 0.65,
        "x": 0.286,
        "y": 0.156
      },
      "kind": "table",
      "text": "Calculation of Constant Currency Revenue for the Three Months Ended September 30, 2023 September 30, 2022 Reported Revenue Constant Currency Revenue¹ Revenue as Reported Changes in Exchange Rates³ Revenue (Non-GAAP)¹ Revenue as Reported Amount Pct. Amount Pct. Contact Lens 228 4 232 222 6 3% 10 5% Consumer² 420 9 429 375 45 12% 54 14% Surgical Consumables 93 (1) 92 85 8 9% 7 8% Surgical Implantables4 45 (1) 44 45 - 0% (1) -2% Surgical Equipment 47 (1) 46 42 5 12% 4 10% Lumify 44 - 44 30 14 47% 14 47% Ocuvite + PreserVision 104 - 104 98 6 6% 6 6% Artelac 30 - 30 27 3 11% 3 11% Premium IOLS 13 (1) 12 9 4 44% 3 33% Vyzulta 19 1 20 13 6 46% 7 54% Contact Lens (excluding impact of distribution facility disruptions) 233 4 237 222 11 5% 15 7% International Pharmaceuticals² 70 - 70 67 3 4% 3 4% Surgical Implantables excluding EyeCee One IOL 45 (1) 44 40 5 13% 4 10%",
      "attrs": {},
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "81946b0b-dd25-4d30-b3a5-8d6dc6524e59",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.077,
        "w": 0.91,
        "x": 0.045,
        "y": 0.036
      },
      "kind": "title",
      "text": "Reconciliation of Reported Revenue to Constant Currency Revenue¹ and Constant Currency Revenue Growth¹ ($M)",
      "attrs": {},
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3709e188-91e8-4630-9f55-df79aaf2fcc9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}